

Open Peer Review on Qeios

Anti-CD22 CAR-expressing T Lymphocytes

National Cancer Institute

Source

National Cancer Institute. <u>Anti-CD22 CAR-expressing T Lymphocytes</u>. NCI Thesaurus. Code C128556.

A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigen (TAA) CD22 and fused to one or more co-stimulatory, TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD22 CAR-expressing T-lymphocytes, express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing B-cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.

Qeios ID: GQ2O84 · https://doi.org/10.32388/GQ2O84